Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Xbrane Biopharma - Filing #689992

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	10 322 SEK	—	—	—	—	—	5 165 SEK	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	176 990 SEK	—	—	—	—	—	127 418 SEK	—	—	—	—	—
Current assets	513 524 SEK	—	—	—	—	—	561 008 SEK	—	—	—	—	—
Non-current liabilities	29 058 SEK	—	—	—	—	—	37 019 SEK	—	—	—	—	—
Current liabilities	236 569 SEK	—	—	—	—	—	219 667 SEK	—	—	—	—	—
Revenue	—	—	57 618 SEK	—	—	—	—	—	—	—	10 709 SEK	—
Profit (loss) from continuing operations	—	—	168 513 SEK	—	—	—	—	—	—	—	183 226 SEK	—
Profit (loss) from discontinued operations	—	—	4 001 SEK	—	—	—	—	—	—	—	5 150 SEK	—
Profit (loss)	—	—	172 513 SEK	—	172 513 SEK	—	—	—	—	—	188 376 SEK	188 376 SEK
Other comprehensive income	—	—	5 157 SEK	—	—	5 157 SEK	—	—	—	1 220 SEK	1 220 SEK	—
Comprehensive income	—	– SEK	167 356 SEK	– SEK	172 513 SEK	5 157 SEK	—	– SEK	– SEK	1 220 SEK	187 156 SEK	188 376 SEK